Table 1.
Antimicrobial Consumption Measured by Days of Therapy (DOT) per 100 Patient Days (PD)
| Antibiotic | Intensive Care Units, DOT per 100 PD | |||
|---|---|---|---|---|
| COVID-19 | Non–COVID-19 | COVID-19/Non–COVID-19, % | P Value | |
| All antibiotics | 134.4 | 109.2 | 123.1 | <.001 |
| Amoxicillin/clavulanate | 22.4 | 5.0 | 448.0 | |
| Azithromycin | 21.3 | 4.8 | 443.8 | |
| Cefepime | 22.8 | 12.5 | 182.4 | |
| Meropenem | 11.7 | 23.8 | 49.2 | |
| Piperacillin/tazobactam | 3.3 | 9.1 | 36.3 | |
| Vancomycin | 5.6 | 18.8 | 29.8 | |
| Emergency department | ||||
| All antibiotics | 218.1 | 70.4 | 309.8 | <.001 |
| Amoxicillin/clavulanate | 59.7 | 17.5 | 341.1 | |
| Azithromycin | 71.5 | 2.8 | 2553.6 | |
| Cefepime | 28.5 | 11.4 | 250.0 | |
| Ceftazidime | 3.5 | 2.9 | 120.7 | |
| Cefuroxime | 16.0 | 10.1 | 158.4 | |
| Metronidazole | 3.5 | 3.6 | 97.2 | |
| Piperacillin/tazobactam | 5.6 | 3.4 | 164.7 | |
| Clinical ward | ||||
| All antibiotics | 172.4 | 62.4 | 276.3 | <.001 |
| Amoxicillin/clavulanate | 41.1 | 4.8 | 856.3 | |
| Azithromycin | 43.8 | 2.1 | 2,085.7 | |
| Cefepime | 17.0 | 7.9 | 215.2 | |
| Cefuroxime | 5.4 | 2.5 | 216.0 | |
| Meropenem | 6.2 | 8.6 | 72.1 | |
| Piperacillin/tazobactam | 7.9 | 6.6 | 119.7 | |
| Sulfamethoxazole and trimethoprim | 3.0 | 4.0 | 75.0 | |
| Vancomycin | 3.7 | 3.6 | 102.8 | |